Sinopharm Group Co. Ltd. (OTCMKTS:SHTDY – Get Free Report) saw a large drop in short interest in May. As of May 15th, there was short interest totaling 11,536 shares, a drop of 72.8% from the April 30th total of 42,380 shares. Based on an average trading volume of 163,961 shares, the days-to-cover ratio is currently 0.1 days.
Sinopharm Group Trading Down 0.3%
Shares of OTCMKTS SHTDY traded down $0.03 during mid-day trading on Friday, hitting $10.78. 21,043 shares of the stock traded hands, compared to its average volume of 61,850. Sinopharm Group has a twelve month low of $10.57 and a twelve month high of $14.87. The firm has a 50 day simple moving average of $12.37 and a two-hundred day simple moving average of $12.91.
About Sinopharm Group
Sinopharm Group Co, Ltd. (OTCMKTS:SHTDY) is one of China’s largest integrated healthcare companies and an indirect subsidiary of the state-owned China National Pharmaceutical Group Co, Ltd. The company operates through two primary segments—pharmaceutical distribution and retail pharmacy—offering comprehensive supply chain solutions that span procurement, storage, transportation and sales of medical products. With a broad portfolio that includes prescription drugs, over-the counter medicines, medical devices and consumables, Sinopharm serves hospitals, clinics, retail pharmacies and other healthcare institutions across mainland China.
In its distribution business, Sinopharm leverages an extensive logistics network, comprising hundreds of distribution centers and thousands of delivery vehicles, to ensure timely delivery of pharmaceuticals under stringent temperature-controlled conditions.
Featured Stories
- Five stocks we like better than Sinopharm Group
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
- Palomar’s High-Risk Insurance Strategy Is Paying Off Big
Receive News & Ratings for Sinopharm Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinopharm Group and related companies with MarketBeat.com's FREE daily email newsletter.
